JAMA Network Home
Sign In
Research Letter

Budget Impact Analysis of Gene Therapies for Recessive Dystrophic Epidermolysis Bullosa

JAMA Dermatology 10.1001/jamadermatol.2026.3240

September 09, 2026 at 11:00 AM EDT

Read the full article

This economic evaluation investigated the budget impact associated with gene therapy treatment of autosomal recessive dystrophic epidermolysis bullosa.

Corresponding Author: Adam J. N. Raymakers, PhD, Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, 41 Ave Louis Pasteur, Boston MA 02115 (araymakers@bwh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2026.3240?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=090926

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks